

Comparison of Carotid-Femoral and Brachial-Ankle Pulse-Wave Velocity in Association With Target Organ Damage in the Community-Dwelling Elderly Chinese: The Northern Shanghai Study

Yuyan Lu, MD;* Mengyun Zhu, MD;* Bin Bai, MD; Chen Chi, MD; Shikai Yu, MD; Jiadela Teliewubai, MD; Henry Xu, MD; Kai Wang, MD; Jing Xiong, MD; Yiwu Zhou, MD; Hongwei Ji, MD; Ximin Fan, MD; Xuejing Yu, MD; Jue Li, MD, PhD; Jacques Blacher, MD, PhD; Yi Zhang, MD, PhD; Yawei Xu, MD, PhD

Background—Carotid-femoral pulse-wave velocity (cf-PWV) and brachial-ankle PWV (ba-PWV) are the 2 most frequently applied PWV measurements. However, little is known about the comparison of hypertensive target organ damage (TOD) with cf-PWV and ba-PWV.

Methods and Results—A total of 1599 community-dwelling elderly subjects (age >65 years) in northern Shanghai were recruited from June 2014 to August 2015. Both cf-PWV and ba-PWV were measured using SphygmoCor and VP1000 systems, respectively. Within the framework of comprehensive cardiovascular examinations, risk factors were assessed, and asymptomatic TOD, including left ventricular mass index, peak transmitral pulsed Doppler velocity/early diastolic tissue Doppler velocity (E/Ea), carotid intima-media thickness, arterial plaque, creatinine clearance rate, and urinary albumin-creatinine ratio were all evaluated. Both PWVs were significantly associated with male sex, age, waist/hip circumference, fasting plasma glucose, and systolic blood pressure, and ba-PWV was also significantly related to body mass index. Both PWVs were significantly correlated with most TOD. When cf-PWV and ba-PWV were both or separately put into the stepwise linear regression model together with cardiovascular risk factors and treatment, only cf-PWV, but not ba-PWV, was significantly associated with carotid intima-media thickness and creatinine clearance rate ($P<0.05$). When cf-PWV and ba-PWV were both or separately put into the same full-mode model after adjustment for confounders, only cf-PWV, but not ba-PWV, showed significant association with carotid intima-media thickness and creatinine clearance rate ($P<0.05$). Similar results were observed in logistic regression analysis.

Conclusions—Taken together, in the community-dwelling elderly Chinese, cf-PWV seems to be more closely associated with hypertensive TOD, especially vascular and renal TOD, as compared with ba-PWV.

Clinical Trial Registration—URL: <http://www.clinicaltrials.gov>. Unique identifier: NCT02368938. (*J Am Heart Assoc.* 2017;6:e004168. DOI: 10.1161/JAHA.116.004168.)

Key Words: brachial-ankle pulse-wave velocity • cardiovascular disease risk factors • carotid-femoral pulse-wave velocity • target organ damage

Pulse-wave velocity (PWV) has been widely accepted in clinical practice as a gold standard of arterial stiffness,¹ which contributes to vascular diseases through phasic mechanical stresses and stretch imposed on vessels as well as shear stress and endothelial dysfunction.^{2,3} Carotid-femoral PWV (cf-PWV) and brachial-ankle PWV (ba-PWV) are

the 2 most frequently applied PWV measurements. The former is recommended as a clinical marker for cardiovascular risk stratification in hypertensives by the European Society of Hypertension (ESH) and European Society of Cardiology (ESC)^{4,5} as well as the American Heart Association,⁶ whereas the latter is widely used and investigated in Asia.^{2,7,8}

From the Department of Cardiology, Shanghai Tenth People's Hospital (Y.L., M.Z., B.B., C.C., S.Y., J.T., H.X., K.W., J.X., Y. Zhou, H.J., X.F., X.Y., Y. Zhang, Y.X.), Department of Prevention (J.L.), and Key Laboratory of Arrhythmias, Ministry of Education (J.L.), Tongji University School of Medicine, Shanghai, China; Diagnosis and Therapeutic Center, Hôtel-Dieu, AP-HP, Paris Descartes University, Paris, France (J.B.).

*Dr Lu and Dr Zhu contributed equally to this work.

Correspondence to: Yi Zhang, MD, PhD, or Yawei Xu, MD, PhD, FACC, Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Middle Road, Shanghai 200072, China. E-mails: yizshcn@gmail.com or xuyawei@tongji.edu.cn

Received September 24, 2016; accepted January 5, 2017.

© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

As a velocity, PWV can be conveniently measured as the distance divided by the time interval between 2 selected points of the arterial system.⁵ Of note, unlike cf-PWV, there is no real artery passing through the 2 selected points in the calculation of ba-PWV. Because ba-PWV is an estimated velocity, and the “path” contains both elastic and muscular arteries,⁵ cf-PWV traveling through only the elastic aorta should be regarded as a better indicator. The cf-PWV has been validated for its prognostic significance of future cardiovascular events in various clinical investigations, such as patients with hypertension, diabetes, and renal failure, the general population, and apparently healthy subjects.^{4,9-15} Nevertheless, Sheng et al¹⁶ indicated that, in 3876 participants of whom 2292 (59.1%) were hypertensive patients, ba-PWV predicted mortality in elderly Chinese who showed markedly increased PWV and hypertension during the median follow-up of 5.9 years. Consistently, Yu et al² also observed that, in 86 apparently healthy subjects and 234 patients with various degrees of abnormality in cardiac structure and function, ba-PWV was more representative of arterial load of the left ventricle (LV) than cf-PWV, probably because ba-PWV encompasses a greater extent of the arterial tree than cf-PWV. Thus, it is controversial whether cf-PWV or ba-PWV is more representative of arterial stiffness and which PWV has a more pronounced prognostic value. Because asymptomatic hypertensive target organ damage (TOD) is a very prevalent and critical prodrome of cardiovascular events and mortality as well as arterial aging, we investigated the association of hypertensive TOD with cf-PWV and ba-PWV within the framework of cardiovascular risk assessment in a community-based elderly cohort.

Methods

Study Design

The Northern Shanghai Study is a prospective, ongoing, and multistage cohort study with the objective of investigating the cardiovascular risk assessment system in elderly Chinese. From June 2014 to August 2015, subjects were recruited if they were (1) aged 65 years or more, (2) local residents from urban communities in the north of Shanghai, and (3) available for long-term follow-up. Exclusion criteria included (1) severe cardiac disease (New York Heart Association Class IV) or end-stage renal disease (chronic kidney disease >4), (2) malignant tumor with life expectancy less than 5 years, and (3) stroke history within 3 months. Finally, 1721 subjects were invited, of whom 1599 (92.9%) were enrolled. The Northern Shanghai Study was authorized and financially supported by the Shanghai municipal government (Grant ID 2013ZYJB0902) and was approved by the Ethics Committee of Shanghai Tenth People’s Hospital. Written

informed consent was obtained from all subjects after relevant information had been provided to them and their relatives.

Social, Clinical, and Biological Parameters

As previously described,¹⁷ information obtained from the questionnaire contained sex, age, weight, and height, smoking habits, family history of premature cardiovascular diseases (CVD), history of diabetes mellitus, hypertension, cardio- or cerebrovascular diseases, renal diseases, and usage of medications.

Venous blood samples and urine samples were obtained in subjects after an overnight fast. Biological markers, including plasma low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, plasma creatinine, and urinary microalbumin and creatinine were assayed by standard methods in the Department of Laboratory Medicine of Shanghai Tenth People’s Hospital. Fasting plasma glucose was measured with the glucose-oxidase method. Creatinine clearance rate (CCR) was calculated by the modified Modification of Diet in Renal Disease formula for Chinese as follows: $CCR (mL/[min \cdot 1.73 m^2]) = 175 \times (\text{plasma creatinine})^{-1.234} \times \text{age}^{-0.179}$ (women $\times 0.79$).¹⁸ Urinary microalbumin divided by urinary creatinine was defined as urinary albumin-creatinine ratio (UACR).

Measurement of Blood Pressures and Ankle-Brachial Index

Blood pressure (BP) of each subject was measured in the morning with the electronic device by specialized physicians 3 times after at least 10 minutes of rest in the sitting position. The average of the 3 BP readings was calculated and used in the subsequent statistical analysis. Pulse pressure was defined as the difference between systolic (SBP) and diastolic BP.

Bilateral brachial and ankle BPs were automatically and simultaneously measured to calculate the ankle-brachial index (calculated as ankle SBP divided by brachial SBP) using the VP1000 system (Omron, Kyoto, Japan).

Pulse-Wave Velocity

The order of cf-PWV and ba-PWV measurements was randomly chosen by the coin-tossing method. The cf-PWV was measured using applanation tonometry (SphygmoCor, AtCor Medical, Sydney, Australia), according to the European Expert Consensus on Arterial Stiffness.¹⁹ First, peripheral BP was recorded twice using the Omron device with an interval of 3 minutes after a rest about 10 minutes. Second, the superficial distance covered by the pulse-wave was measured

directly from the carotid to the femoral artery. Third, pressure waveforms in the right carotid and right femoral arteries were recorded for each subject, and transit time for each artery was automatically calculated via ECG data by the “foot-to-foot” method. Finally, cf-PWV was calculated by traveling distance divided by traveling time, and an operator index greater than 80% indicated high-quality waveforms.

The ba-PWV was measured using the VP1000 system (Omron) as previously described.¹⁶ In brief, pulse waves of brachial and posterior tibial arteries were measured via pressure cuffs on both arms and both ankles in the supine position after a 10-minute rest. The device estimated the travel path from body height and calculated ba-PWV automatically as the travel path divided by the time difference between brachial and ankle arterial pulse waves. Right ba-PWV was used for analysis in the present study. Of note, ba-PWV was excluded when ankle-brachial index was <0.9, which is considered indicative of peripheral arterial diseases.

Ultrasonography

The common carotid artery intima-media thickness (CIMT) was measured using the MyLab 30 Gold cardiovascular system (ESAOTE SpA, Genoa, Italy) with a 7.5-MHz probe. As previously described,¹ measurements were taken on the left common carotid artery 2 cm from the bifurcation and were always performed on plaque-free arterial segments. Three measurements of CIMT were taken, and the average value was used for further analysis. Simultaneously, the presence or absence of plaques in the left and right carotid arteries was recorded.

M-mode and 2-dimensional echocardiography were performed using the same device with a 3.5-MHz probe, according to the guidelines of the American Society of Echocardiography.²⁰ LV ejection fraction was measured by M-mode echocardiography using the adjusted Teicholz formula.²¹ Left ventricular end-diastolic diameter (LVEDd), interventricular septal (IVSd), and posterior wall thickness at end-diastole (PWTd) were measured by M-mode or 2-dimensional echocardiography from the parasternal view^{17,20} and then used to calculate left ventricular mass (LVM),²² which was further standardized for body size as left ventricular mass index (LVMI) by dividing by body surface area (BSA).

$$\text{LVM (g)} = 0.8 \times \{1.04 \times [(LVEDd + PWTd + IVSd)^3 - (LVEDd)^3]\} + 0.6$$

and

$$\text{LVMI (g/m}^2\text{)} = \text{LVM} \div \text{BSA}$$

Transmitral flow velocity was detected by 2-dimensional Doppler echocardiography according to the American Society

of Echocardiography²³: peak transmitral pulsed Doppler velocity/early diastolic tissue Doppler velocity (E/Ea) was calculated for the evaluation of LV diastolic function. In addition, left atrial volume was calculated using the model formula and standardized to body size by dividing by BSA to give the left atrial volume index (LAVI):

$$\text{LAVI (mL/m}^2\text{)} = [\pi \times (\text{SA1} \times \text{SA2} \times \text{LA})/6] \div \text{BSA}$$

where SA1 is the M-mode left atrial dimension in the parasternal short-axis view, and SA2 and LA are measurements of short and long axes in the apical 4-chamber view at ventricular end-systole.²⁴ All ultrasonographic measurements were performed by a single experienced sonographer.

Definition of Hypertensive TOD

Asymptomatic hypertensive TOD include cardiac, arterial, and renal TOD. Left ventricular hypertrophy was defined as LVMI ≥ 115 g/m² (male) or LVMI ≥ 95 g/m² (female). LV diastolic dysfunction was assessed by E/Ea and other evidence of abnormal LV relaxing and filling, such as enlarged left atrial volume and increased LVM.²⁴ Specifically, diastolic dysfunction was defined as E/Ea ≥ 15 , or $8 < E/Ea < 15$ with any of the following: LAVI > 40 mL/m² or LVMI > 149 g/m² (male) or LVMI ≥ 122 g/m² (female).^{24,25} Arterial TOD was defined as increased CIMT (CIMT > 900 μm) or as the presence of arterial plaque,²⁶ chronic kidney diseases (CCR < 60 mL/[min $\cdot 1.73$ m²]), and microalbuminuria (UACR > 30).

Statistical Analysis

Quantitative and qualitative parameters were presented as means \pm standard deviation and numbers with the percentage in parentheses, compared between men and women by Student t test and chi-squared test, respectively. Multivariate linear regressions were conducted to detect the association of conventional cardiovascular risk factors with cf-PWV and ba-PWV, such as sex, age, smoking, family history of premature CVD, waist/hip circumference, body mass index (BMI), fasting plasma glucose, LDL cholesterol, HDL cholesterol, and SBP. Pearson correlation analysis was applied to investigate the correlation of asymptomatic hypertensive TOD with cf-PWV and ba-PWV, respectively. Further, stepwise multivariate linear and logistic regressions were conducted to investigate the association of hypertensive TOD with cf-PWV and ba-PWV. Only variables staying in the final model were presented. In addition, cf-PWV and ba-PWV were both or separately put into the same full-mode regression models after adjustments for confounders to detect the regression coefficients and odds ratios (ORs) of PWVs in hypertensive TOD. It is noteworthy that age and SBP were forced into all models of regressions because PWVs were strongly

Table 1. Characteristics of Participants by Sex

	Overall (n=1599)	Men(n=711)	Women (n=888)	P Value
Cardiovascular risk factors				
Age, y	72.6±6.0	72.7±5.9	72.6±6.1	0.96
Smoker, n (%)	366 (22.9)	351 (49.4)	15 (1.7)	<0.001*
Family history of premature CVD, n (%)	324 (20.3)	124 (17.4)	200 (22.6)	0.01*
Waist circumference, cm	85.8±9.7	87.8±9.8	84.1±9.4	<0.001*
Hip circumference, cm	97.1±7.2	97.2±6.8	97.0±7.5	0.50
Body mass index, kg/m ²	23.9±3.5	23.9±3.3	23.9±3.6	0.92
Fasting plasma glucose, mmol/L	5.69±1.70	5.72±1.67	5.67±1.73	0.55
High-density lipoprotein cholesterol, mmol/L	1.38±0.36	1.28±0.33	1.46±0.36	<0.001*
Low-density lipoprotein cholesterol, mmol/L	3.20±0.85	3.04±0.85	3.33±0.83	<0.001*
Systolic blood pressure, mm Hg	134.3±17.7	134.3±16.8	134.3±18.4	0.95
Asymptomatic hypertensive target organ damage				
Pulse pressure, mm Hg	55.4±15.2	54.4±14.0	56.2±16.1	0.02*
Left ventricular mass index, g/m ²	90.0±28.6	90.5±28.8	89.6±28.4	0.54
Carotid intima-medium thickness, μm	612.1±148.2	633.0±159.5	595.5±136.4	<0.001*
Right ankle-brachial index	1.05±0.13	1.05±0.14	1.05±0.12	0.40
Creatinine clearance rate, mL/[min·1.73 m ²]	92.4±21.7	88.3±20.0	95.8±22.5	<0.001*
Urinary albumin-creatinine ratio, mg/g	54.9±181.6	51.1±108.3	58.0±224.4	0.45
cf-PWV, m/s	9.4±2.3	9.3±2.4	9.5±2.2	0.32
ba-PWV, cm/s	1870.5±379.0	1838.1±355.9	1895.0±393.9	0.01*
Diseases and treatment				
Hypertension, n (%)	843 (52.7)	385 (54.2)	458 (51.6)	0.31
Diabetes mellitus, n (%)	312 (19.5)	137 (19.3)	175 (19.7)	0.99
Hyperlipidemia, n (%)	549 (34.3)	231 (32.5)	318 (35.8)	0.16
Antihypertensive treatment, n (%)	801 (50.1)	365 (51.3)	436 (49.1)	0.37
Antidiabetic treatment, n (%)	279 (17.4)	123 (17.3)	156 (17.6)	0.89
Antihyperlipidaemic treatment, n (%)	259 (16.2)	102 (14.3)	157 (17.7)	0.07

Data are means±standard deviation or numbers with percentages in parentheses. Student t test and chi-squared test were conducted to compare the differences between men and women for quantitative and qualitative variables, respectively. Creatinine clearance rate was calculated with modified Modification of Diet in Renal Disease formula for Chinese. ba-PWV indicates brachial-ankle pulse-wave velocity; cf-PWV, carotid-femoral pulse-wave velocity; CVD, cardiovascular diseases.

* $P<0.05$.

dependent on the 2 variables. Statistical analysis was performed using SAS software, version 9.3 (SAS Institute, Cary, NC). $P<0.05$ was considered statistically significant.

Results

Participants

Characteristics of participants by sex are presented in Table 1, including conventional cardiovascular risk factors, asymptomatic hypertensive TOD, and diseases and treatment. The 1599 participants included 711 (44.5%) men, 312 (19.5%) participants with diabetes, 843 (52.7%) participants with

hypertension, of whom 799 (93.9%) were taking antihypertensive agents. Men, compared with women, had significantly more smokers (49.4% vs 1.7%, $P<0.001$), higher waist circumference (87.8±9.8 vs 84.1±9.4 cm, $P<0.001$), lower incidence of family history of premature CVD (17.4% vs 22.6%, $P=0.01$), lower HDL cholesterol (1.28±0.33 vs 1.46±0.36 mmol/L, $P<0.001$), lower LDL cholesterol (3.04±0.85 vs 3.33±0.83 mmol/L, $P<0.001$), lower pulse pressure (54.4±14.0 vs 56.2±16.1 mm Hg, $P=0.02$), higher CIMT (633.0±159.5 vs 595.5±136.4 μm, $P<0.001$), lower CCR (88.3±20.0 vs 95.8±22.5 mL/[min·1.73 m²], $P<0.001$), and lower ba-PWV (1838.1±355.9 vs 1895.0±393.9 cm/s, $P=0.01$).

Table 2. Association of Cardiovascular Risk Factors With cf-PWV and ba-PWV

Cardiovascular Risk Factors	cf-PWV			ba-PWV		
	Regression Coefficient	P Value	Incremental R ²	Regression Coefficient	P Value	Incremental R ²
Sex (1=male, 0=female)	-0.36	0.007*	0.003	-83.5	<0.001*	0.010
Age, y	0.12	<0.001*	0.082	20.4	<0.001*	0.091
Smoker (1=smoker, 0=nonsmoker)	0.16	0.29		-15.9	0.55	
Family history of premature CVD (1=yes, 0=no)	0.10	0.45		-9.1	0.68	
Waist/hip circumference	2.5	0.011*	0.004	356.0	0.035*	0.003
Body mass index, kg/m ²	0.002	0.92		-8.3	0.007*	0.002
Fasting plasma glucose, mmol/L	0.201	<0.001*	0.026	26.9	<0.001*	0.016
Low-density lipoprotein cholesterol, mmol/L	0.089	0.15		11.5	0.29	
High-density lipoprotein cholesterol, mmol/L	-0.26	0.10		-26.2	0.34	
Systolic blood pressure, mm Hg	0.038	<0.001*	0.133	8.3	<0.001*	0.178
Total R ²	0.252			0.301		

Multivariate linear regressions were conducted to investigate the association of cardiovascular risk factors with cf-PWV and ba-PWV. ba-PWV indicates brachial-ankle pulse-wave velocity; cf-PWV, carotid-femoral pulse-wave velocity; CVD, cardiovascular diseases.

*P<0.05.

Association of Cardiovascular Risk Factors With cf-PWV and ba-PWV

Conventional cardiovascular risk factors, including sex, age, smoking, family history of premature CVD, waist/hip circumference, BMI, fasting plasma glucose, HDL cholesterol, LDL cholesterol, and SBP, were put into a multivariate linear regression model to investigate their association with cf-PWV and ba-PWV. As shown in Table 2, both cf-PWV and ba-PWV were significantly and consistently associated with male sex, age, waist/hip circumference, fasting plasma glucose, and SBP (P<0.04), whereas ba-PWV was also significantly related

to BMI (P=0.007). The total R² values of the full models with cf-PWV and ba-PWV were 0.252 and 0.301, respectively.

Correlation of Asymptomatic Hypertensive TOD With cf-PWV and ba-PWV

In the correlation analysis of PWVs with hypertensive TOD, cf-PWV was significantly correlated with all parameters of asymptomatic TOD (P<0.01), and ba-PWV was also significantly correlated with all parameters (P<0.05), except CCR (P=0.077) (Table 3).

Table 3. Correlation of Asymptomatic Hypertensive Target Organ Damage With cf-PWV and ba-PWV

Asymptomatic Hypertensive Target Organ Damage	cf-PWV		ba-PWV	
	r	P Value	r	P Value
Left ventricular mass index	0.12	<0.001*	0.11	<0.001*
E/Ea	0.07	0.004*	0.09	0.001*
Carotid intima-media thickness	0.13	<0.001*	0.08	0.003*
Creatinine clearance rate	-0.15	<0.001*	-0.05	0.077
Urinary albumin-creatinine ratio	0.09	<0.001*	0.06	0.041*

Pearson correlation analyses were conducted to investigate the association of asymptomatic hypertensive target organ damage with cf-PWV and ba-PWV. ba-PWV indicates brachial-ankle pulse-wave velocity; cf-PWV, carotid-femoral pulse-wave velocity; E/Ea, peak transmitral pulsed Doppler velocity/early diastolic tissue Doppler velocity.

*P<0.05.

Association of cf-PWV and ba-PWV With Asymptomatic Hypertensive TOD

Because PWVs were greatly dependent on age and blood pressure, the 2 variables (age and SBP) were forced into all models in the following linear and logistic regression analysis to investigate the association of cf-PWV and ba-PWV with hypertensive TOD. As shown in Table 4, when both cf-PWV and ba-PWV were put into the stepwise linear regression model, together with cardiovascular risk factors and number of subjects on medications, only cf-PWV, but not ba-PWV, was significantly associated with CIMT (5.05±2.03 μm, P=0.001, incremental R²=0.005) and CCR (-0.60±0.29 mL/[min·1.73 m²], P=0.041, incremental R²=0.003). Consistently, when they were separately put into the same model, only cf-PWV showed significant association with CIMT (5.11±1.82 μm, P=0.005), and CCR (-0.79±0.26 mL/[min·1.73 m²], P=0.002) (Table 5). In addition, the same results were observed

Table 4. Determinants of Hypertensive TOD Analyzed by Multivariate Linear Regressions When cf-PWV and ba-PWV Are Both Put Into the Same Models

Cardiovascular Risk Factors, Treatment, and PWVs	Cardiac TOD				Vascular TOD		Renal TOD			
	LVMI		E/Ea		CIMT		CCR		UACR	
	$\beta \pm SE$	<i>P</i> Value								
Age, y	0.63±0.13	<0.001	0.01±0.02	0.49	2.55±0.76	<0.001	-1.1±0.1	<0.001	1.8±1.0	0.068
Systolic blood pressure, mm Hg	0.22±0.05	<0.001	0.04±0.01	<0.001	0.39±0.25	0.12	0.14±0.04	<0.001	-0.24±0.35	0.48
Sex (1=male, 0=female)	-1.01±0.25	<0.001	26.0±10.0	0.01	-7.3±1.2	<0.001
Smoker (1=smoker, 0=nonsmoker)	0.67±0.30	0.03	17.7±12.0	0.14
Family history of premature CVD (1=yes, 0=no)	-0.49±0.25	0.053
Waist/hip circumference	39.5±13.5	0.004
Body mass index, kg/m ²	0.89±0.26	<0.001	4.0±1.7	0.02
Fasting plasma glucose, mmol/L	-0.92±0.45	0.040	1.0±0.4	0.01	5.6±3.2	0.0828
Low-density lipoprotein cholesterol, mmol/L	10.0±4.8	0.04	-1.8±0.7	0.008
High-density lipoprotein cholesterol, mmol/L	6.3±1.6	<0.001
Antihypertensive treatment (1=yes, 0=no)	5.8±1.7	<0.001	0.38±0.22	0.079	-3.0±1.2	0.017	34.3±11.9	0.004
Antidiabetic treatment (1=yes, 0=no)	3.3±1.7	0.0572
Antihyperlipidemic treatment (1=yes, 0=no)	0.54±0.27	0.045
cf-PWV, m/s	5.05±2.03	0.01	-0.60±0.29	0.041
ba-PWV, cm/s
Total R ²	0.108		0.061		0.043		0.155		0.020	

Stepwise multivariate linear regressions were conducted to investigate the determinants of hypertensive TOD. Age and systolic blood pressure were forced into all models. Only variables staying in the final model are presented. ... indicates nonsignificance; ba-PWV indicates brachial-ankle pulse-wave velocity; CCR, creatinine clearance rate; cf-PWV, carotid-femoral pulse-wave velocity; CIMT, carotid intima-media thickness; CVD, cardiovascular diseases; E/Ea, peak transmitral pulsed Doppler velocity/early diastolic tissue Doppler velocity; LVMI, left ventricular mass index; TOD, target organ damage; UACR, urinary albumin-creatinine ratio.

in full-mode linear regression models after adjustments for confounders, regardless of whether cf-PWV and ba-PWV were both or separately put into the models (Figure, panels A and B).

Moreover, when both cf-PWV and ba-PWV were put into the stepwise logistic regression model in Table 6, together with conventional cardiovascular risk factors and number of subjects on medications, only cf-PWV, but not ba-PWV, was significantly associated with increased CIMT (OR=1.34, 95% CI 1.02-1.76, *P*=0.037) and microalbuminuria (OR=1.22, 95%

CI 1.05-1.41, *P*=0.009). Similarly, when they were separately put into the stepwise linear regression model, cf-PWV showed significant association with arterial plaque (OR=1.19, 95% CI 1.03-1.36, *P*=0.015) and microalbuminuria (OR=1.21, 95% CI 1.06-1.38, *P*=0.004), whereas ba-PWV was significantly associated with increased CIMT (OR=1.36, 95% CI 1.01-1.82, *P*=0.042) and microalbuminuria (OR=1.20, 95% CI 1.04-1.38, *P*=0.013) (Table 7). Finally, both PWVs were put into the full-mode logistic regression model after adjustments for

Table 5. Determinants of Hypertensive TOD Analyzed by Multivariate Linear Regressions When cf-PWV and ba-PWV Are Separately Put Into the Same Models

PWVs	Cardiac TOD				Vascular TOD		Renal TOD			
	LVMI		E/Ea		CIMT		CCR		UACR	
	$\beta \pm SE$	P Value								
cf-PWV, m/s	5.11±1.82	0.005	-0.79±0.26	0.002
ba-PWV, cm/s

Stepwise multivariate linear regressions were conducted to investigate the determinants of hypertensive TOD. Age and systolic blood pressure were forced into all models. Only variables staying in the final model are presented. ... indicates nonsignificance; ba-PWV indicates brachial-ankle pulse-wave velocity; CCR, creatinine clearance rate; cf-PWV, carotid-femoral pulse-wave velocity; CIMT, carotid intima-media thickness; E/Ea, peak transmitral pulsed Doppler velocity/early diastolic tissue Doppler velocity; LVMI, left ventricular mass index; TOD, target organ damage; UACR, urinary albumin-creatinine ratio.

confounders, and only cf-PWV showed a significant correlation with microalbuminuria (OR=1.23, 95% CI 1.07-1.42, P=0.045) (Figure, panel C). However, when they were separately put into the full-mode logistic regression model, cf-PWV was significantly related with arterial plaque (OR=1.22, 95% CI 1.06-1.40, P=0.005), chronic kidney disease (OR=1.26, 95% CI 1.02-1.56, P=0.035), and microalbuminuria (OR=1.26, 95% CI 1.11-1.43, P<0.001), whereas ba-PWV was significantly associated only with microalbuminuria (OR=1.23, 95% CI 1.07-1.42, P=0.004) in Figure, panel D.

Discussion

There were 2 major findings in the present study. First, both cf-PWV and ba-PWV exhibited similar associations with various cardiovascular risk factors in the elderly, including male sex, age, waist/hip circumference, fasting plasma glucose, and SBP. Second, hypertensive TOD, especially vascular and renal TOD, may be more closely associated with cf-PWV than with ba-PWV in the study cohort of community-dwelling elderly.




Figure. The cf-PWV and ba-PWV in association with hypertensive TOD after adjustments for confounders. A and B, Regression coefficients of cf-PWV and ba-PWV are presented after adjustments for confounders using multivariate linear regressions when cf-PWV and ba-PWV were both (A) or separately (B) put into the same full-mode model. C and D, Odds ratios of cf-PWV and ba-PWV were presented after adjustments for confounders using logistic regressions when cf-PWV and ba-PWV were both (C) or separately (D) put into the same full-mode model. ba-PWV indicates brachial-ankle pulse-wave velocity; CCR, creatinine clearance rate; cf-PWV, carotid-femoral pulse-wave velocity; CIMT, carotid intima-media thickness; CVD, cardiovascular diseases; E/Ea, peak transmitral pulsed Doppler velocity/early diastolic tissue Doppler velocity; LVMI, left ventricular mass index; TOD, target organ damage; UACR, urinary albumin-creatinine ratio. Definitions of hypertensive TOD are presented in Methods.

Table 6. Determinants of Hypertensive TOD Analyzed by Logistic Regressions When cf-PWV and ba-PWV Are Both Put Into the Same Models

Cardiovascular Risk Factors, Treatment, and PWVs	Cardiac TOD			Vascular TOD			Renal TOD					
	Left Ventricular Hypertrophy		Diastolic Dysfunction		Increased CIMT		Arterial Plaque		Chronic Kidney Diseases		Microalbuminuria	
	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value
Age (y), +1 SD	1.19 (1.04-1.37)	0.012	0.99 (0.82-1.22)	0.987	1.13 (0.84-1.53)	<0.001	1.43 (1.24-1.63)	<0.001	2.24 (1.74-2.90)	<0.001	1.13 (0.99-1.29)	0.075
Systolic blood pressure (mm Hg), +1 SD	1.30 (1.13-1.50)	<0.001	1.31 (1.07-1.60)	0.009	0.95 (0.70-1.29)	0.757	1.07 (0.95-1.21)	0.276	0.78 (0.57-1.05)	0.099	1.13 (0.99-1.30)	0.079
Sex (1=male, 0=female)	0.26 (0.19-0.35)	<0.001	0.57 (0.38-0.86)	0.007	0.61 (0.47-0.79)	<0.001
Smoker (1=smoker, 0=nonsmoker)	2.56 (1.41-4.64)	0.002	1.50 (1.11-2.03)	0.009
Family history of premature CVD (1=yes, 0=no)	0.72 (0.52-0.98)	0.037
Waist/hip circumference, +1 SD	1.29 (1.12-1.49)	<0.001	1.23 (1.08-1.40)	0.003
Body mass index (kg/m ²), +1 SD
Fasting plasma glucose (mmol/L), +1 SD	1.22 (1.07-1.39)	0.003
Low-density lipoprotein cholesterol (mmol/L), +1 SD	1.31 (1.01-1.69)	0.042
High-density lipoprotein cholesterol (mmol/L), +1 SD	0.72 (0.53-0.96)	0.028
Antihypertensive treatment (1=yes, 0=no)	1.56 (1.17-2.09)	0.003	1.72 (1.12-2.65)	0.014	1.93 (1.05-3.54)	0.035	1.70 (1.30-2.22)	<0.001
Antidiabetic treatment (1=yes, 0=no)	1.58 (1.13-2.21)	0.008
Antihyperlipidaemic treatment (1=yes, 0=no)	1.63 (1.19-2.24)	0.003
cf-PWV (m/s), +1 SD	1.34 (1.02-1.76)	0.037	1.22 (1.05-1.41)	0.009
ba-PWV (cm/s), +1 SD

Stepwise logistic regressions were conducted to investigate the determinants of hypertensive TOD. Age and systolic blood pressure were forced into all models. Only variables staying in the final model are presented. ... indicates nonsignificance; ba-PWV indicates brachial-ankle pulse-wave velocity, cf-PWV, carotid-femoral pulse-wave velocity; CIMT, carotid intima-media thickness; CVD, cardiovascular diseases; OR, odds ratio; TOD, target organ damage. Definitions of hypertensive TOD were presented in Methods.

Table 7. Determinants of Hypertensive TOD Analyzed by Logistic Regressions When cf-PWV and ba-PWV Are Separately Put Into the Same Models

PWVs	Cardiac TOD				Vascular TOD				Renal TOD			
	Left Ventricular Hypertrophy		Diastolic Dysfunction		Increased CIMT		Arterial Plaque		Chronic Kidney Diseases		Microalbuminuria	
	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value
cf-PWV (m/s), +1 SD	1.19 (1.03-1.36)	0.015	1.21 (1.06-1.38)	0.004
ba-PWV (cm/s), +1 SD	1.36 (1.01-1.82)	0.042	1.20 (1.04-1.38)	0.013

Stepwise logistic regressions were conducted to investigate the determinants of hypertensive TOD. Age and systolic blood pressure were forced into all models. Only variables staying in the final model are presented. ... indicates nonsignificance; ba-PWV indicates brachial-ankle pulse-wave velocity; cf-PWV, carotid-femoral pulse-wave velocity; CIMT, carotid intima-media thickness; CVD, cardiovascular diseases; OR, odds ratio; TOD, target organ damage. Definitions of hypertensive TOD were presented in Methods.

For 2 decades, arterial stiffness was recognized as an important predictor of CVD and mortality. In theory, increased arterial stiffness is related to elasticity loss and reduced compliance in the arteries, which can further increase blood pressure.²⁷ In turn, elevated blood pressure leads to vessel wall structure remodeling and vessel dysfunction to compensate for changes in wall stress, which can further exacerbate the arterial stiffness.²⁷⁻²⁹ Aging as an independent risk factor of hypertension and arterial stiffness also plays an important role in the vicious circle.³⁰ In young individuals there is a stiffness gradient between the aorta and muscular arteries, which is reduced with increasing age through replacement of the degenerated elastic fibers by collagenous fibers in the vascular wall.^{2,31} Additionally, intima-media thickening, as a result of these modifications in vascular fibers, also influences arterial stiffening.³² Of note, it was known that aortic PWV increased nonlinearly and exponentially with aging, so it is possible that this process accelerated in the presence of hypertension and in the elderly.^{5,31,33,34} In the present study we focused on subjects aged over 65 years to investigate the association of arterial stiffness estimated by cf-PWV and ba-PWV with cardiovascular risk factors and hypertensive TOD, aiming to identify the better indicator of arterial stiffening in the elderly.

Both cf-PWV and ba-PWV, as the most common indexes of arterial stiffness, have been widely used in clinical practice, with greater usage of cf-PWV in the Western countries and greater usage of ba-PWV in Asia.^{4,8} For cf-PWV, pressure transducers are placed on target arteries for the acquisition of carotid and femoral pressure waveforms and the calculation of the velocity. The resulting PWV is taken as representative of the PWV for the entire aorta. On the other hand, for ba-PWV, there is no true arterial pathway linking the measurement sites (brachial to ankle). The resulting estimated PWV is taken as representative of the PWV for the entirety of the central and peripheral arterial system.^{35,36} Both cf-PWV and ba-PWV were strongly linked with cardiovascular risk, and there was a positive association between cf-PWV and ba-PWV in previous publications.^{1,2,35,37-40} In accordance with these studies, we found that both cf-PWV and ba-PWV were significantly associated with male sex, aging, obesity, glucose profile, and high BP, and we also observed a significant and positive association between them in our present studies (data not shown). In addition, ba-PWV was significantly associated with BMI. This finding may be attributable to the formula applied in the software built into the Omron ba-PWV device and to the influence of adiposity on muscular arterial reflected wave in the elderly.

In literature,^{2,16,41,42} cf-PWV and ba-PWV have been separately analyzed for their association with symptomatic TOD because hypertensive TOD is of great importance and is recognized as the intermediate outcome connecting cardiovascular risk factors and cardiovascular events and mortality.

Because they are the 2 most common indicators of arterial stiffening in clinical practice, it makes sense to do a comparative analysis of cf-PWV and ba-PWV in their associations with TOD. Nevertheless, the magnitude of the association of TOD with cf-PWV and ba-PWV remains a subject of debate. In theory and based on the current guidelines for BP management, cf-PWV was recognized as the golden standard of arterial stiffness as well as an important predictor of future cardiovascular risk.⁵ However, because ba-PWV was more widely applied in Asia, some data suggested the opposite opinion. For instance, Yu et al² indicated that, in a Chinese population, ba-PWV correlated better with cardiac and vascular structure and function than cf-PWV. On the contrary, we found that, in this community-based elderly Chinese population, there was no significant difference between cf-PWV and ba-PWV in their association with cardiac TOD. However, cf-PWV was more closely related to vascular and renal abnormalities than ba-PWV, but with weak correlations and poor R^2 values. The relatively small correlation coefficients and R^2 values of the present study may be attributable to the complicated confounders and relatively weak association among the intermediate outcomes in the real-world “healthy” elderly subjects. Nevertheless, it is also noteworthy that our findings were reliable because they were double checked by the multiple linear and logistic regression models and with many variables adjusted. As to the discrepancies existing between the cardiac and vascular/renal TOD in association with those 2 PWVs, the main reason responsible for them may be that cardiac structure and function indicated by LVMI and E/Ea were less affected by arterial stiffness as compared with vascular and renal abnormalities.

Our results were consistent with previous studies and current guidelines,^{4,5} indicating the superiority of cf-PWV over ba-PWV in the association with vascular and renal abnormalities in the elderly. It is true that ba-PWV can be more conveniently measured by an inexperienced or untrained practitioner, and accumulating data have indicated its significant prognostic value for cardiovascular events and mortality, such as the similar prospective study in a rural area of Shanghai.¹⁶ We indicated that, from the viewpoint of organ-protection-driven BP management, cf-PWV, but not ba-PWV, was recommended for the Chinese elderly, especially for those suffering from the vascular and renal abnormalities.

Limitations

The findings of the present study need to be interpreted within the context of its limitations. First, as a cross-sectional study, we focused only on the comparative analysis of cf-PWV and ba-PWV in association with cardiovascular risk factors and hypertensive TOD in the elderly but without any intervention or causality interpretation. With ongoing follow-

up studies, we will be able to provide more prospective data in the future. Second, we could not fully adjust for the influence of different medications on PWVs, such as various antihypertensive, antidiabetic, and antihyperlipidemic drugs, which may have differing effects on central and peripheral arterial stiffness.

Perspectives

In light of the high burden of cardiovascular diseases on the aging society, an accurate assessment of arterial stiffness is of great importance and should be strongly recommended in the elderly. In the present study cf-PWV was more closely associated with vascular and renal TOD in comparison with ba-PWV in the elderly. However, the mechanisms remain incompletely understood. Therefore, further laboratory research is warranted to investigate the underlying mechanisms.

Conclusions

Cf-PWV seems to be superior to ba-PWV in association with asymptomatic hypertensive TOD, especially vascular and renal TOD, in the community-dwelling elderly Chinese population.

Acknowledgments

The authors thank all the investigators and subjects who participated in the Northern Shanghai Study and thank Changjiang Yu from Harbin Medical University Cancer Hospital for his critical comments and suggestions on this manuscript.

Sources of Funding

This study was authorized and financially supported by the Shanghai Municipal Government (Grant ID 2013ZYJB0902; 15GWZK1002). Dr Yi Zhang was supported by the National Nature Science Foundation of China (Grant ID 81300239; 81670377).

Disclosures

None.

References

- Zhang Y, Agnoletti D, Protogerou AD, Topouchian J, Wang JG, Xu Y, Blacher J, Safar ME. Characteristics of pulse wave velocity in elastic and muscular arteries: a mismatch beyond age. *J Hypertens*. 2013;31:554–559; discussion 559.
- Yu WC, Chuang SY, Lin YP, Chen CH. Brachial-ankle vs carotid-femoral pulse wave velocity as a determinant of cardiovascular structure and function. *J Hum Hypertens*. 2008;22:24–31.
- Kass DA. Ventricular arterial stiffening: integrating the pathophysiology. *Hypertension*. 2005;46:185–193.

4. Mancía G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Rullope LM, Schmieder RE, Sirnes PA, Sleight P, Vliigimaa M, Waerber B, Zannad F; Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2013;31:1281–1357.
5. Zhang Y, Agnoletti D, Xu Y, Wang JG, Blacher J, Safar ME. Carotid-femoral pulse wave velocity in the elderly. *J Hypertens*. 2014;32:1572–1576; discussion 1576.
6. Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, Heffernan KS, Lakatta EG, McEniery CM, Mitchell GF, Najjar SS, Nichols WW, Urbina EM, Weber T; American Heart Association Council on Hypertension. Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association. *Hypertension*. 2015;66:698–722.
7. Sugawara J, Hayashi K, Yokoi T, Cortez-Cooper MY, DeVan AE, Anton MA, Tanaka H. Brachial-ankle pulse wave velocity: an index of central arterial stiffness? *J Hum Hypertens*. 2005;19:401–406.
8. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S, Yamamoto Y. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. *Hypertens Res*. 2002;25:359–364.
9. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. *Hypertension*. 2001;37:1236–1241.
10. Roderjan CN, Cardoso CR, Ferreira MT, Muxfeldt ES, Salles GF. Correlates of aortic stiffness progression in patients with resistant hypertension: importance of clinic and ambulatory blood pressure changes. *J Hypertens*. 2015;33:827–834; discussion 834–835.
11. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? *Circulation*. 2002;106:2085–2090.
12. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. *Circulation*. 1999;99:2434–2439.
13. Chirinos JA, Khan A, Bansal N, Dries DL, Feldman HI, Ford V, Anderson AH, Kalleem R, Lash JP, Ojo A, Schreiber M, Sheridan A, Strelsin J, Teal V, Roy J, Pan Q, Go AS, Townsend RR; CRIC Study Investigators. Arterial stiffness, central pressures, and incident hospitalized heart failure in the chronic renal insufficiency cohort study. *Circ Heart Fail*. 2014;7:709–716.
14. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. *Circulation*. 2006;113:664–670.
15. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler MM, Witteman JC. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. *Circulation*. 2006;113:657–663.
16. Sheng CS, Li Y, Li LH, Huang QF, Zeng WF, Kang YY, Zhang L, Liu M, Wei FF, Li GL, Song J, Wang S, Wang JG. Brachial-ankle pulse wave velocity as a predictor of mortality in elderly Chinese. *Hypertension*. 2014;64:1124–1130.
17. Zhang Y, Protogerou AD, Iaria P, Safar ME, Xu Y, Blacher J. Prognosis in the hospitalized very elderly: the PROTEGER study. *Int J Cardiol*. 2013;168:2714–2719.
18. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY; Chinese eGFR Investigation Collaboration. Improved GFR estimation by combined creatinine and cystatin C measurements. *Kidney Int*. 2007;72:1535–1542.
19. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, Schillaci G, Segers P, Vermeersch S, Weber T; Artery Society; European Society of Hypertension Working Group on Vascular Structure and Function; and European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *J Hypertens*. 2012;30:445–448.
20. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W; American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. *Eur J Echocardiogr*. 2006;7:79–108.
21. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. *Am J Cardiol*. 1976;37:1–11.
22. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichel N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol*. 1986;57:450–458.
23. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA; Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2002;15:167–184.
24. Zhang Y, Kollias G, Argyris AA, Papaioannou TG, Tountas C, Konstantonis GD, Achimastos A, Blacher J, Safar ME, Sfrikakis PP, Protogerou AD. Association of left ventricular diastolic dysfunction with 24-h aortic ambulatory blood pressure: the SAFAR study. *J Hum Hypertens*. 2015;29:442–448.
25. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC Jr, Jacobsen SJ, Rodeheffer RJ. Progression of left ventricular diastolic dysfunction and risk of heart failure. *JAMA*. 2011;306:856–863.
26. Gaye B, Mustafic H, Laurent S, Perier MC, Thomas F, Guibout C, Tafflet M, Pannier B, Boutouyrie P, Jouven X, Empana JP. Ideal cardiovascular health and subclinical markers of carotid structure and function: the Paris Prospective Study III. *Arterioscler Thromb Vasc Biol*. 2016;36:2115–2124.
27. Chen X, Huang B, Liu M, Li X. Effects of different types of antihypertensive agents on arterial stiffness: a systematic review and meta-analysis of randomized controlled trials. *J Thorac Dis*. 2015;7:2339–2347.
28. Payne RA, Wilkinson IB, Webb DJ. Arterial stiffness and hypertension: emerging concepts. *Hypertension*. 2010;55:9–14.
29. Wallace SM, Yasmin, McEniery CM, Maki-Petaja KM, Booth AD, Cockcroft JR, Wilkinson IB. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. *Hypertension*. 2007;50:228–233.
30. Sun Z. Aging, arterial stiffness, and hypertension. *Hypertension*. 2015;65:252–256.
31. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasan RS, Levy D. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. *Hypertension*. 2004;43:1239–1245.
32. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. *Hypertension*. 2005;45:1050–1055.
33. Reference Values for Arterial Stiffness Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. *Eur Heart J*. 2010;31:2338–2350.
34. Tomiyama H, Arai T, Koji Y, Yambe M, Motobe K, Zaydun G, Yamamoto Y, Hori S, Yamashina A. The age-related increase in arterial stiffness is augmented in phases according to the severity of hypertension. *Hypertens Res*. 2004;27:465–470.
35. Tanaka H, Munakata M, Kawano Y, Ohishi M, Shoji T, Sugawara J, Tomiyama H, Yamashina A, Yasuda H, Sawayama T, Ozawa T. Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. *J Hypertens*. 2009;27:2022–2027.
36. Choo J, Shin C, Barinas-Mitchell E, Masaki K, Willcox BJ, Seto TB, Ueshima H, Lee S, Miura K, Venkitachalam L, Mackey RH, Evans RW, Kuller LH, Sutton-Tyrrell K, Sekikawa A. Regional pulse wave velocities and their cardiovascular risk factors among healthy middle-aged men: a cross-sectional population-based study. *BMC Cardiovasc Disord*. 2014;14:5.
37. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. *Hypertension*. 1999;33:1111–1117.
38. Jang SY, Ju EY, Huh EH, Kim JH, Kim DK. Determinants of brachial-ankle pulse wave velocity and carotid-femoral pulse wave velocity in healthy Koreans. *J Korean Med Sci*. 2014;29:798–804.
39. Sutton-Tyrrell K, Newman A, Simonsick EM, Havlik R, Pahor M, Lakatta E, Spurgeon H, Vaitkevicius P. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. *Hypertension*. 2001;38:429–433.
40. Meyer ML, Tanaka H, Palta P, Patel MD, Campbell R, Couper D, Cheng S, Al Qunaibet A, Poon AK, Heiss G. Repeatability of central and peripheral pulse wave velocity measures: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Hypertens*. 2015;29:470–475.
41. Matsui Y, Ishikawa J, Shibasaki S, Shimada K, Kario K. Association between home arterial stiffness index and target organ damage in hypertension: comparison with pulse wave velocity and augmentation index. *Atherosclerosis*. 2011;219:637–642.
42. Gomez-Marcos MA, Recio-Rodriguez JI, Patino-Alonso MC, Agudo-Conde C, Gomez-Sanchez L, Gomez-Sanchez M, Rodriguez-Sanchez E, Garcia-Ortiz L. Protocol for measuring carotid intima-media thickness that best correlates with cardiovascular risk and target organ damage. *Am J Hypertens*. 2012;25:955–961.



Comparison of Carotid–Femoral and Brachial–Ankle Pulse–Wave Velocity in Association With Target Organ Damage in the Community –Dwelling Elderly Chinese: The Northern Shanghai Study

Yuyan Lu, Mengyun Zhu, Bin Bai, Chen Chi, Shikai Yu, Jiadela Teliewubai, Henry Xu, Kai Wang, Jing Xiong, Yiwu Zhou, Hongwei Ji, Ximin Fan, Xuejing Yu, Jue Li, Jacques Blacher, Yi Zhang and Yawei Xu

J Am Heart Assoc. 2017;6:e004168; originally published February 20, 2017;
doi: 10.1161/JAHA.116.004168

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://jaha.ahajournals.org/content/6/2/e004168>